Case Study

Apr 4, 2016

Introduction

Resistant hypertension (RH) is frequently encountered in primary care and a significant clinical challenge.  After a combination of 3 or 4 guideline-recommended treatments have been used, it remains unclear what the next best “add on” treatment for RH should be.  The recently published PATHWAY-2 study provides some evidence.  Read the iForumRx commentary.

 

Case Presentation:

HL is a 57 year-old Caucasian male...

Comments: 0      Views: 1,749


Mar 22, 2012

AB is a 64 year old man with a past medical history of hypertension, diabetes, and ischemic cardiomyopathy.  He presented to his cardiologist, Dr. Smith, 6 months ago with palpitations associated with shortness of breath and dizziness and was diagnosed with atrial fibrillation.  He has been on warfarin therapy with a goal INR of 2-3 since that time.  Today he presents to anticoagulation clinic for routine follow-up and states, “I just can’t keep coming to appointments every 4 weeks like this...

Comments: 0      Views: 7,204


Aug 8, 2011

In May 2011, the National Heart Lung and Blood Institute (NHLBI) announced the early termination of the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health (better known as the AIM-HIGH) trial due to lack of benefit from extended release niacin when add to simvastatin (+/- ezetimibe).  AIM-HIGH was a double-blind, randomized, placebo-controlled outcomes trial with over 3000...

Comments: 0      Views: 5,652


Aug 8, 2011

In May 2011, the National Heart Lung and Blood Institute (NHLBI) announced the early termination of the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health (better known as the AIM-HIGH) trial due to lack of benefit from extended release niacin when add to simvastatin (+/- ezetimibe).  AIM-HIGH was a double-blind, randomized, placebo-controlled outcomes trial with over 3000...

Comments: 0      Views: 4,144